Skip to main content

Table 2 Bone markers and densitometry data at baseline and 1 year later

From: A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab

Group Baseline 1 year P
Control    
   Osteocalcin 21.2 ± 13.4 20.7 ± 11.5 NS
   CTX-I 418 ± 227 391 ± 259 NS
   Parathyroid hormone 32.0 ± 19.1 36.0 ± 19.7 NS
   25-hydroxycholecalciferol 21.2 ± 10.4 22.8 ± 10.5 NS
   Femoral neck BMD 0.797 ± 0.162 0.770 ± 0.162 <0.001
   Lumbar BMD 0.896 ± 0.142 0.861 ± 0.142 <0.001
Infliximab    
   Osteocalcin 18.4 ± 9.7 15.7 ± 10.9 NS
   CTX-I 482 ± 386 452 ± 271 NS
   Parathyroid hormone 29.1 ± 15.4 32.6 ± 15.5 NS
   25-hydroxycholecalciferol 17.9 ± 10.1 19.6 ± 9.2 NS
   Femoral neck BMD 0.807 ± 0.156 0.809 ± 0.151 NS
   Lumbar BMD 0.930 ± 0.142 0.928 ± 0.136 NS
  1. Values are shown for each parameter at baseline and at 1 year, expressed as mean ± standard deviation. In each group, data were compared using the Student's paired t-test for continuous variables, between baseline and 1 year. BMD, bone mineral density; CTX-I, C-terminal cross-linking telopeptide of type I collagen.